Literature DB >> 10812288

Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study.

G Pozzi1, G Conte, S De Risio.   

Abstract

Trazodone is a non-tricyclic antidepressant drug with specific antagonistic activities at 5-HT(2) and alpha-1 adrenoceptors. We test the efficacy of trazodone (T) compared with clonidine (C) in rapid opiate detoxification (ROD) from methadone after reduction to a daily maintenance dose </=20 mg. Forty five inpatients were consecutively assigned either to T (n=30) or to C (n=15) treatment in a 7-day ROD protocol with naltrexone administration starting at day 4. The maximum daily dosage was 800 mg for T and 1.2 mg for C. The retention rate was similar in both groups (93.3%). Overall, T was as effective as C in the ROD protocol. T was slightly superior in controlling some subjective and psychological symptoms, but not under naltexone challenge. No severe adverse effects were observed. We conclude that T is effective, safe and well-tolerated in acute withdrawal from methadone. Further investigation is needed to test the effectiveness and safety of T in ultra-rapid protocols and its usefulness in long-term administration to detoxified addicts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812288     DOI: 10.1016/s0376-8716(99)00125-8

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  4 in total

1.  Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Authors:  Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2017-01-10       Impact factor: 18.112

Review 2.  Opioid Management: Initiating, Monitoring, and Tapering.

Authors:  W Michael Hooten
Journal:  Phys Med Rehabil Clin N Am       Date:  2020-03-11       Impact factor: 1.784

Review 3.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

4.  Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series.

Authors:  Marianna Mazza; Emanuele Caroppo; Giuseppe Marano; Georgios D Kotzalidis; Carla Avallone; Giovanni Camardese; Delfina Janiri; Lorenzo Moccia; Alessio Simonetti; Luigi Janiri; Gabriele Sani
Journal:  Int J Environ Res Public Health       Date:  2022-06-16       Impact factor: 4.614

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.